ALN-ANG3 Investigational ANGPTL3-silencing RNAi therapy licensed to Regeneron, in Phase 2 development for diabetic kidney disease within the partnered metabolic portfolio.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-ANG3.
Add it to your Products I use list and share why you use it.